Biotech and Pharma

IT infrastructure services for Biotech and Pharmaceutical Companies

8 Biotech Pharma trends that will shape the industry


It is no news the Biotech Pharma market is becoming more globalized and is challenged to adapt to several new market realities by revising their business models, marketing, and operational processes.

Price reductions, slower growth, and regulatory compliance require companies in the Biotech Pharma industry to drive more margin out of their current models.  Collaboration, secure file sharing and mobile device access across a global marketplace will need to occur. To accomplish these goals IT infrastructure has to be reliable, scalable, secure and “high-performance.”

The easiest and least expensive way to accomplish this is to buy “IT as a Service.”  Order what you need like storage capacity, file sharing services, compliant security hosting and mobile device management and only pay a monthly fee for what you need.  No capital expenses.

To illustrate why IT as a Service provides the best value, we listed some of the key trends in the Biotech Pharma industry and how they all require some element of IT infrastructure or support.


Trend #1: Personalized smart health for the smartphone society

The old aphorism “An apple a day keeps the doctor away,” may take on a whole new meaning. Apple released its iHealth app for the iPhone and with it, a toolbox for healthcare technology companies to begin creating their own health-based apps. The fruits of this labor should begin to ripen in the coming year, leading to a steady stream of new apps competing on the iTunes app store.

Offering patients a way to manage their healthcare will free up GPs’ time and allow patients greater autonomy in managing their health. But is the world ready for this level of control?

According to research by consultancy company PriceWaterhouseCooper (PwC) physicians are already onboard with healthcare apps being used autonomously by patients, with 86% of doctors saying that they believed that healthcare apps would become important to physicians over the next 5 years.

One of the first health providers to embrace the new iHealth technology was Mayo Clinic. They developed an app for doctors which allows patients to share data with their HCPs in real time, from other apps they use to monitor their health, such as a blood pressure monitor.

“We believe Apple’s HealthKit will revolutionize how the health industry interacts with people,” said John Noseworthy, Mayo Clinic president and CEO.synoptek-technology-consulting-meeting

To provide secure smartphone access, you need a Managed Services Provider whose expertise includes managing the security and connectivity for a full-range of both Apple and Windows devices, like Synoptek.


Trend #2: “Pharmerging” markets increase contributions to innovation

There is a growing importance of emerging markets regarding where the pharmaceutical industry is turning for additional market growth and profitability.  The increased spending power of these so-called pharmerging markets has meant that new pharma products need to be launched on a more global scale than ever before. Expect pharmerging markets to increasingly influence the global strategy for pharma.

These markets have become the fastest area of growth in Patent Cooperation Treaty (PCT) applications, with Russia and China outpacing the rest of Europe and North America. This trend will continue with emerging markets turning their focus towards health issues particularly affecting their populations.

To address this trend, you need a“Global” Managed Services Provider that can provide hosting, monitoring, and management of all types of IT devices worldwide.  Synoptek was rated number 15 on the MSP501 Global Managed Service Provider list and can provide and manage the global IT infrastructure needed to support these emerging biotech and pharma markets.


Trend #3: Rising healthcare costs drive innovation

According to an IMS Health study, the annual growth in global healthcare spending was around $70 billion in 2014 up from $26 billion in 2012. This dramatic increase in spending is forcing governments to reassess healthcare costs and apply pressure to bring these costs down.

One way in which costs are being kept down is through new healthcare innovations. Some of these innovations will be the hi-tech, wearable devices and apps discussed in our first trend.

As we discussed in our market access checklist along with value-based assessments, payers are also focusing on individualized healthcare. As such, companies that pair new products with companion diagnostics can charge a premium, while those that do not may not gain market access. Diagnostics are largely unheralded compared to medicines, but personalized medicine is entirely reliant on companion diagnostics. How will payers react to the fast-moving developments in mobile health? Will they, as we have seen with companion diagnostic, soon also favor medicines that are companioned by apps that help patients monitor and manage their disease?

Personalized medicine will need to rely on secure, compliant application platforms built on a scalable infrastructure hosted in secure datacenters globally.  Additionally, when patients experience access problems, a 24×7 Help Desk Service Center should be available.  Synoptek provides all of these services.


Trend #4: Growing conflict between access to medicines and affordability

In terms of market access, the rising cost of healthcare is being met by increasing demands for new evidence and definitions of positive health outcomes. As PwC comments in their report: “The contact-usgrowing conflict between drug access and affordability will create fresh pressure for data that show these expensive medications work better than others and are worth the premium.”

What’s more, communicating new evidence about drug value to key stakeholders – insurers, physicians, and patients – will require additional skills and techniques. Account managers, sales reps and patient engagement specialists will need to collaborate with quantitative analysts or bioinformaticists to tailor new drug information for each different audience.

By using new and sophisticated apps, pharma companies will be able to customize the new drug information much more quickly and easily and demonstrate value to payers in new and engaging ways.

An IT infrastructure capable of providing secure collaboration while supporting new applications will be needed to take full advantage of bringing value and new applications to patients.


Trend #5: Transparency becomes a key driver of innovation

In October 2014, 520 organizations – including physician groups, patient advocates, government regulatory bodies and one large pharmaceutical company, GlaxoSmithKline – signed the AllTrials petition, calling for the results of all clinical trials to be published.

The European Medical Association (EMA) has also made the decision to begin publishing clinical trial data used to support the approval and authorization of new drugs in Europe in the coming year. Their hope, much like the AllTrials initiative, is that by making clinical trial data publicly available they will be helping to avoid duplication of trials, foster innovation, and encourage the development of new medicines by the pharma industry.

With more data available and less duplication of efforts, the pharma industry can begin to naturally pool their R&D resources to develop effective, profitable, and innovative new healthcare solutions at a lower cost to the end user.

This pooled information will need to securely reside on servers with global access.  Synoptek’s top-tier data center facilities are supported by the best in power, cooling, security, and data storage. Synoptek’s hosting facilities are capable of providing: hosting, managed cloud services, connections to multiple carriers, co-location, and disaster recovery to biotech and pharma companies on a global basis.


Trend #6: Collaborate to innovate

Innovation will also be driven by an increase in collaboration across the pharma sector. To thrive in the increasingly competitive modern pharma market, companies will have to work together to develop innovative new products, services, and solutions, as well as share skills and expertise.

A great example of this type of collaboration in action is the recently announced collaboration between AbbVie, a research-based biopharmaceutical company, and the Google-backed life sciences firm Calico. By using Calico’s technical expertise to establish a new research and development facility, and with AbbVie using its scientific and clinical development support and commercial experience to bring discoveries to market, the two companies hope to discover, develop and market new therapies for patients with age-related diseases, such as cancer.

One of the key components of this collaboration is shared-use of a high-performance IT infrastructure across multiple geographic locations.


Trend #7: More mergers and acquisitions as the recalibration of the industry continues

Global M&A deals in the healthcare/life sciences sector hit an unprecedented $317.4 billion in the first half of 2014, and the second half saw some huge deals, such as Allergan’s $66 billion acquisition of Actavis. That’s not even taking into account the scrapped $55 billion takeover bid for Shire by AbbVie or the failed $118 billion takeover of AstraZeneca by Pfizer – which would have been the largest acquisition in pharma history.

We think there will continue to be series of high-profile acquisition bids. Some will succeed, and others will fail. It is not unlikely that Shire will again emerge as a target, possibly for Pfizer who might be looking for a new target after their failed AstraZeneca bid.  Other rumored targets, such as UK’s Smith & Nephew and the Swiss Actelion, might re-emerge on the horizon.

Synoptek has merged many IT environments created through acquisitions.  Our 300 skilled IT professionals are familiar with the steps needed to provide a seamless transition in combining merged IT environments.


Trend #8: The era of smaller and more frequent product launches continuescios-300x222

According to IMS Health, nearly 200 new drugs are forecast to be launched in the next five years, with a high number of new molecular entities (NMEs) expected to be launched annually, continuing a second wave of innovation similar to levels seen in the mid-2000s.

There are currently over 2,000 products in late-stage clinical development, of which a quarter are oncology therapies. Furthermore, the growing number of medicines receiving the FDA’s Breakthrough Therapy Designation is contributing to an acceleration of approvals. Yet the global availability of these new medicines to patients varies significantly by country and disease, with less than half of new products available across all the major developed markets within five years of launch.



If you accept that data is critical to your biotech or pharma business and that the management of that data is equally important, then you want to establish a relationship with a provider like Synoptek that will be a partner with you and not a faceless vendor who just sells a commodity solution to the masses.

Remember that all of our services carry a written guaranteed performance commitment.  We believe in “customer focused” service, and that is why so many Healthcare Providers use our services.


This article based on the blog post from Tribeca Knowledge, Andre Moa / January 9, 2015 –